SCHEMBL1635348

SCHEMBL1635348

COC(=O)c1c2oc3cc(NC(=O)CCNC(=O)OC(C)(C)C)ccc3nc-2c(C)c(Cl)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 2/20 0.40
ADORA3 P0DMS8 2/20 0.39
ABL1 P00519 1/20 0.38
PDGFRB P09619 1/20 0.38
SRC P12931 1/20 0.38
PDGFRA P16234 1/20 0.38
MAPK14 Q16539 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HIF1A Q16665 1/20 0.37
MAPK1 P28482 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
AGPAT2 O15120 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483503 0.93 ADORA3 (0.41) SUV39H2ADORA3ABL1PDGFRBSRC
SCHEMBL1635346 0.85 KDM4E (0.41) SUV39H2ADORA3ABL1PDGFRBSRC
SCHEMBL1636865 0.79 KDM4E (0.41) SUV39H2ADORA3ABL1PDGFRBSRC
SCHEMBL1635427 0.76 TLR7 (0.41) SUV39H2ADORA3ABL1PDGFRBSRC
SCHEMBL1635253 0.71 TLR7 (0.41) SUV39H2ADORA3ABL1PDGFRBSRC
SCHEMBL8692897 0.67 CA1 (0.66) SUV39H2ABL1PDGFRBSRCPDGFRA
SCHEMBL14911359 0.67 SMN1; SMN2 (0.64) KDM4EALDH1A1GAAMAPTMAPK1
SCHEMBL25257824 0.66 FBP1 (0.53) ADORA3ABL1PDGFRBSRCPDGFRA
Trifluoroacetic Acid SCHEMBL1636097 0.66 SMN1; SMN2 (0.45) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL2244763 0.66 ALDH1A1 (0.59) KDM4EALDH1A1HPGDGLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932050-B2 Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2011-04-26 US disclosed
US-20100028926-A1 Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2010-02-04 US disclosed
US-7626018-B2 Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity bioMérieux (FR) 2009-12-01 US disclosed
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity BIOMERIEUX (FR) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity PEPD, CTRL, PREP SUV39H2 2573/4885ADORA3 1435/4885ABL1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.